Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(1):116–123. doi: 10.1038/bjc.1997.19

Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.

A J Swerdlow 1, J A Barber 1, A Horwich 1, D Cunningham 1, S Milan 1, R Z Omar 1
PMCID: PMC2222705  PMID: 9000608

Abstract

Risk of second primary malignancy was assessed in follow-up to June 1991 of 1039 patients first treated for Hodgkin's disease at the Royal Marsden Hospital during 1963-91. A total of 77 second malignancies occurred. There were significantly raised risks of stomach [standardized incidence ratio (SIR)=4.0], lung (SIR=3.8), bone (SIR=26.5), soft tissue (SIR=16.9) and non-melanoma skin (SIR=3.9) cancers, non-Hodgkin's lymphoma (SIR=4.6), and acute and non-lymphocytic leukaemia (SIR=31.3), with a relative risk of 3.3 for all second cancers other than non-melanoma skin cancer. Solid cancer risk was raised to a similar extent in patients treated only with radiotherapy (SIR=2.6, P<0.001), only with chemotherapy (SIR=2.1, P=0.08) and with both (SIR=3.1, P<0.001). Leukaemia risk was raised only in those receiving chemotherapy, whether alone or with radiotherapy. The relative risk for solid cancers was much greater in patients who were younger at first treatment (trend P<0.001), whereas leukaemia risk was greatest for those first treated at ages 25-44. For solid cancers (P<0.001) but not leukaemia (P=0.05) there was a strong gradient of greater relative risks at younger attained ages. The relative risk of second cancers overall was 27.5 at ages under 25 and 2.0 at ages 55 and above. Leukaemia and solid cancer risks in patients treated with chlorambucil, vinblastine, procarbazine and prednisone (ChlVPP) were not significantly greater than those in patients treated with mustine, vincristine, procarbazine and prednisone (MOPP). Number of cycles of chemotherapy was significantly related to risk of leukaemia (P<0.001), and there was a trend in the same direction for solid cancers (P=0.07). The study adds to evidence that alkylating chemotherapy may increase the risk of solid cancers, and that ChlVPP does not provide a less carcinogenic alternative to MOPP chemotherapy. The very large relative risks found for solid cancers at young attained ages and in patients treated when young may have important implications as, in the long term, the majority of second malignancies after Hodgkin's disease are solid cancers. The risks of solid malignancies need clarification by larger collaborative epidemiological studies.

Full text

PDF
116

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahamsen J. F., Andersen A., Hannisdal E., Nome O., Abrahamsen A. F., Kvaløy S., Høst H. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol. 1993 Feb;11(2):255–261. doi: 10.1200/JCO.1993.11.2.255. [DOI] [PubMed] [Google Scholar]
  2. Biti G., Cellai E., Magrini S. M., Papi M. G., Ponticelli P., Boddi V. Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):25–31. doi: 10.1016/0360-3016(94)90222-4. [DOI] [PubMed] [Google Scholar]
  3. Boivin J. F., Hutchison G. B., Zauber A. G., Bernstein L., Davis F. G., Michel R. P., Zanke B., Tan C. T., Fuller L. M., Mauch P. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst. 1995 May 17;87(10):732–741. doi: 10.1093/jnci/87.10.732. [DOI] [PubMed] [Google Scholar]
  4. Boivin J. F., O'Brien K. Solid cancer risk after treatment of Hodgkin's disease. Cancer. 1988 Jun 15;61(12):2541–2546. doi: 10.1002/1097-0142(19880615)61:12<2541::aid-cncr2820611225>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  5. Glicksman A. S., Pajak T. F., Gottlieb A., Nissen N., Stutzman L., Cooper M. R. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1982 Apr;66(4):1035–1044. [PubMed] [Google Scholar]
  6. Hancock S. L., Tucker M. A., Hoppe R. T. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993 Jan 6;85(1):25–31. doi: 10.1093/jnci/85.1.25. [DOI] [PubMed] [Google Scholar]
  7. Henry-Amar M., Pellae-Cosset B., Bayle-Weisgerber C., Hayat M., Cosset J. M., Carde P., Tubiana M. Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience. Recent Results Cancer Res. 1989;117:270–283. doi: 10.1007/978-3-642-83781-4_30. [DOI] [PubMed] [Google Scholar]
  8. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol. 1992 Sep;3 (Suppl 4):117–128. doi: 10.1093/annonc/3.suppl_4.s117. [DOI] [PubMed] [Google Scholar]
  9. Kaldor J. M., Day N. E., Band P., Choi N. W., Clarke E. A., Coleman M. P., Hakama M., Koch M., Langmark F., Neal F. E. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer. 1987 May 15;39(5):571–585. doi: 10.1002/ijc.2910390506. [DOI] [PubMed] [Google Scholar]
  10. Kaldor J. M., Day N. E., Clarke E. A., Van Leeuwen F. E., Henry-Amar M., Fiorentino M. V., Bell J., Pedersen D., Band P., Assouline D. Leukemia following Hodgkin's disease. N Engl J Med. 1990 Jan 4;322(1):7–13. doi: 10.1056/NEJM199001043220102. [DOI] [PubMed] [Google Scholar]
  11. Pedersen-Bjergaard J., Specht L., Larsen S. O., Ersbøll J., Struck J., Hansen M. M., Hansen H. H., Nissen N. I. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987 Jul 11;2(8550):83–88. doi: 10.1016/s0140-6736(87)92744-9. [DOI] [PubMed] [Google Scholar]
  12. Selby P., Patel P., Milan S., Meldrum M., Mansi J., Mbidde E., Brada M., Perren T., Forgeson G., Gore M. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer. 1990 Aug;62(2):279–285. doi: 10.1038/bjc.1990.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sont J. K., van Stiphout W. A., Noordijk E. M., Molenaar J., Zwetsloot-Schonk J. H., Willemze R., Vandenbroucke J. P. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience. Ann Hematol. 1992 Nov;65(5):213–218. doi: 10.1007/BF01703947. [DOI] [PubMed] [Google Scholar]
  14. Swerdlow A. J., Douglas A. J., Hudson G. V., Hudson B. V., Bennett M. H., MacLennan K. A. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ. 1992 May 2;304(6835):1137–1143. doi: 10.1136/bmj.304.6835.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Swerdlow A. J., Douglas A. J., Vaughan Hudson G., Vaughan Hudson B., MacLennan K. A. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer. 1993 Nov;68(5):1006–1011. doi: 10.1038/bjc.1993.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tucker M. A., Coleman C. N., Cox R. S., Varghese A., Rosenberg S. A. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988 Jan 14;318(2):76–81. doi: 10.1056/NEJM198801143180203. [DOI] [PubMed] [Google Scholar]
  17. Young R. C., Bookman M. A., Longo D. L. Late complications of Hodgkin's disease management. J Natl Cancer Inst Monogr. 1990;(10):55–60. [PubMed] [Google Scholar]
  18. van Leeuwen F. E., Chorus A. M., van den Belt-Dusebout A. W., Hagenbeek A., Noyon R., van Kerkhoff E. H., Pinedo H. M., Somers R. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994 May;12(5):1063–1073. doi: 10.1200/JCO.1994.12.5.1063. [DOI] [PubMed] [Google Scholar]
  19. van der Velden J. W., van Putten W. L., Guinee V. F., Pfeiffer R., van Leeuwen F. E., van der Linden E. A., Vardomskaya I., Lane W., Durand M., Lagarde C. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer. 1988 Aug 15;42(2):252–255. doi: 10.1002/ijc.2910420218. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES